Objective: To develop and evaluate a pharmacogenomics information resource for pharmacists. Materials and Methods: We built a pharmacogenomics information resource presenting Food and Drug Administration (FDA) drug product labelling information, refined it based on feedback from pharmacists, and conducted a comparative usability evaluation, measuring task completion time, task correctness and perceived usability. Tasks involved hypothetical clinical situations requiring interpretation of pharmacogenomics information to determine optimal prescribing for specific patients. Results: Pharmacists were better able to perform certain tasks using the redesigned resource relative to the Pharmacogenomic Knowledgebase (PharmGKB) and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. On average, participants completed tasks in 107.5 s using our resource, compared to 188.9 s using PharmGKB and 240.2 s using the FDA table. Using the System Usability Scale, participants rated our resource 79.62 on average, compared to 53.27 for PharmGKB and 50.77 for the FDA table. Participants found the correct answers for 100% of tasks using our resource, compared to 76.9% using PharmGKB and 69.2% using the FDA table. Discussion: We present structured, clinically relevant pharmacogenomic FDA drug product label information with visualizations to help explain the relationships between gene variants, drugs, and phenotypes. The results from our evaluation suggest that user-centered interfaces for pharmacogenomics information can increase ease of access and comprehension. Conclusion: A clinician-focused pharmacogenomics information resource can answer pharmacogenomicsrelated medication questions faster, more correctly, and more easily than widely used alternatives, as perceived by pharmacists.
BACKGROUND AND SIGNIFICANCE
As pharmacogenomics-guided drug decision-making becomes more common, pharmacists seek trustworthy, clinically actionable pharmacogenomics information to guide their decisions. [1] [2] [3] [4] Using information about the interaction between genotypes and medications to inform medication and dosage choices can optimize treatment and prevent adverse medication events, 5 yet that knowledge is not regularly applied. 6, 7 Insufficient pharmacogenomics training, complicated terminology, and a rapidly moving field complicate the task, making clinicians of all types uncertain of their ability to make informed decisions about medications with pharmacogenomics implications.
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Consequences of not knowing a patient's genotype and resulting phenotype can be severe, even fatal, as in the death of a breastfed newborn whose mother was an ultra-rapid metabolizer of codeine, which caused her breast milk to contain toxic levels of codeine's active metabolite, morphine. 10 The Food and Drug Administration (FDA) now requires the boxed warning section of clopidogrel's product label to warn that poor metabolizers of clopidogrel may not be effectively treated by the drug and may have a higher risk of heart attack, stroke, and death than normal metabolizers, 11 implying that genetic testing may be appropriate prior to prescription. With the help of genetic tests, clinicians can ideally prescribe the right dose of the right drug at the right time to the right patient. In some cases, such as with warfarin 1 and clopidogrel, 3 genotyping already informs drug and dose selection in select hospitals. However, medication-related genetic testing is still in its nascent phase, 9, 12 and there is no consensus yet on the usefulness of pharmacogenomics vs other methods to determine drug choice or dosage, [13] [14] [15] [16] further complicating how to use genetic information. In 2011, the Clinical Pharmacogenetic Implementation Consortium (CPIC) began developing clinical guidelines to support biomarker-based clinical decision-making in conjunction with the Pharmacogenomics Knowledgebase and the National Institute of Health's Pharmacogenomics Research Network (www.pgrn.org). 17 As pharmacogenomics becomes more integrated into standard practice, clinicians have an ever greater need for clinically relevant, effectively presented, searchable information that supports accurate interpretation and adoption of treatment recommendations. 18 Multiple efforts exist to support the integration of patientspecific, clinically actionable pharmacogenomics information into practice. Eleven sites in the Electronic Medical Records and Genomics (eMERGE) Network are implementing pharmacogenomics clinical decision support. A recent article found that while these sites have experienced delays and barriers to implementation of pharmacogenomics clinical decision support, these are generally surmountable. 12 The eMERGE group is developing an infobutton that will write genomic medicine information to share genetic testing results with clinicians within the eMERGE network. 19 Trustworthy, clear pharmacogenomic information presented in a clinically useful way and combined with patient data and local or CPIC practice guidelines has the potential to move pharmacogenomics into clinical practice.
As drug information experts poised to support the pharmacogenomics information needs of other clinicians, pharmacists play a key role in pharmacogenomics-informed drug decisions. [20] [21] [22] [23] [24] Meeting pharmacists' information needs is critical to effectively incorporate pharmacogenomics information into decision-making. 22 Multiple resources are available, including the FDA 26 but none of these resources are currently able to provide clinically relevant information at the point of care. The FDA table lists the drugs that are mandated by the FDA to contain relevant pharmacogenomics information, but it requires a minimum of 4 nonobvious clicks to access a product label. The user still has to scan through the entire product label to locate the pharmacogenomic information, which is dispersed throughout the label in multiple sections. PharmGKB aims to provide comprehensive pharmacogenomics information, with an emphasis on the CPIC guidelines, 27 but the utility of practicing pharmacists using it to make prescribing decisions has not been evaluated. In previous work, we developed a semantic model of pharmacogenomics information in product labels and designed a preliminary prototype interface to explore that information. 28 We extracted pharmacogenomics statements from drug product labels and presented that information in a prototype user interface, as a first step toward the goal of providing clinically actionable pharmacogenomics information at the point of care. We also conducted a series of interviews with pharmacists to assess their pharmacogenomics information needs and resource requirements. 29 In this study, we redesigned our prototype pharmacogenomics information resource based on the results of that assessment and conducted a user study comparing it to the original prototype, the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling,   25 and the FDA labeling information in the Pharmacogenomics Knowledge Base. 30 Here, we present the redesigned prototype interface and the results of our evaluation.
MATERIALS AND METHODS

Version 1.0 design
In the initial version of the prototype, the top table provides information about the gene variants, the phenotype, and whether the impact is on the drug's efficacy or toxicity. A pathway diagram illustrates how the drug interacts with the gene product to influence the drug-related phenotype ( Figure 1 ). Below are tabs containing pharmacogenomics information from the annotated structured product labels (SPLs), and recommendations regarding how to change the patient's treatment ( Figure 2 ).
Initial usability study
As part of a previously published study, 29 we asked 14 pharmacists working in a variety of settings to use our initial prototype to answer pharmacogenomics-related medication questions while we observed their behavior. We recruited pharmacists through professional connections of the authors, using a convenience sampling strategy designed to represent the diversity of needs and perspectives associated with different care contexts, including tertiary-care centers, community practices, and private nursing home consulting pharmacies. We used the results of this preliminary usability study to identify problems with the pharmacogenomics information resource interface. These problems, along with the results of our inquiry into pharmacists' perceived information needs, informed a redesign of the prototype. The study was approved by the University of Pittsburgh Institutional Review Board.
Pharmacogenomics resource usability evaluation
We conducted laboratory-based user studies with 16 pharmacists, comparing both versions of our prototype to potential alternative sources of pharmacogenomics information contained in FDA drug product labelling. The FDA table was selected as the authoritative source issued by a key regulatory agency. PharmGKB was selected based on its history as the most comprehensive and well-established pharmacogenomics information resource providing pharmacogenomics information from product labels. Study participants completed 8 pharmacogenomics information tasks that could be answered in all 4 information resources. These tasks asked participants to consider drug and dosage choices appropriate for individuals with various genotypes, along with questions regarding the applicability of testing. The tasks were designed to cover a range of pharmacogenomics concepts that have been identified as important competencies for pharmacists by the American Society of Health System Pharmacists and the Pharmacogenomics Education Program (PharmGenEd) at the University of California, San Diego. 31 The tasks and correct answers were written based on information provided solely within the FDA product label for each relevant drug, as that is the source of pharmacogenomics information provided by all assessed resources. Four of the tasks involved only 1 drug question, and 4 were multidrug questions. The tasks are listed in Table 1 . The order in which tasks and resources were presented was varied among participants using a pseudo-randomization technique, to avoid order effects. The order of tasks was randomly assigned to the first participant and was assigned to each subsequent participant based on that participant, to ensure that each task was performed on each resource an equal number of times. The order of resources was assigned randomly to each participant.
The FDA table and PharmGKB resources were downloaded to the study laptop to guarantee that task completion times would not be dependent on Internet connectivity and network latency. We The pharmacists were instructed to use only the assigned resource for each task and not seek the information on any other sites. We recorded their activity on the screen and their voices simultaneously using SnagIt, a Chrome web browser extension for screen capture. 33 Participants were instructed to highlight the text of the answer to each task on the screen when they found it. Each task had a maximum completion time of 10 min. Tasks that were not completed in this time were marked as incorrect. The task completion time for incorrect and incomplete tasks was measured as the time it took to find the incorrect answer, give up, or reach 10 min. After all 8 tasks were finished, participants completed the System Usability Score (SUS) questionnaire 34 for each resource, to assess perceived usability. Measurements included the time to complete each task from start to finish, the correctness of each answer as determined by the investigators, and the SUS score for each resource. Evaluations took place during July and August 2015 and were conducted at the participants' workplaces. The study was approved by the University of Pittsburgh Institutional Review Board.
Data analysis
Data were analyzed using MiniTab 17 35 and R version 3.2.3.
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Descriptive statistics were used to summarize participant demographics.
We performed a regression analysis to examine task completion time vs task number to assess order effect. For task completion time, we assessed the distribution of the data, which was lognormal. pairwise comparison Bonferroni correction. MiniTab was used for all analyses except the Kruskal-Wallis and Dunn tests, for which R was used. P values were considered significant at .05. We considered 3 types of incorrect answers: the user gave an answer that was wrong, the user failed to find an answer before 10 min, and the user gave up before finding an answer but before the 10-min mark. All of these are considered incorrect, as they are a failure to find the correct answer.
RESULTS
Usability issues
We organized usability issues identified in our initial usability study into 3 categories: layout, information display, and information. The layout was problematic, because the accordion design of the section containing the information from product labels seemed almost invisible. Participants also often failed to notice the Drug Info Links table. As a result, many of the pharmacists were unable to access product label information, and they requested links to other sources despite those links being available. While they liked the illustrations of interactions between drugs and genes, they were often confused by the table containing information about efficacy and toxicity, or how that influenced the phenotype. Pharmacists were also confused by the notation of the gene variants ("star" notation) and they wanted clear recommendations. They were concerned about the source of the information, as it was not clear to them that all the statements originated from FDA-approved product labels. Finally, pharmacists also wanted more general background information about pharmacogenomics, specifically about the drugs and genes, to understand the information presented to them. The problems with version 1.0 of the prototype identified in the initial usability study and the changes made in response are summarized in Table 2 .
The most prominent change to the drug pages ( Figure 3 ) was combining the pathway portion of the page with the table to form a visual map, leading users from interactions between drugs and variants to information about phenotypes, and finally to FDA recommendations. This change was made in response to pharmacists' difficulty in interpreting the table with information about genotype and phenotype. Specifically, our participants requested assistance with interpreting the relationship between genotype, phenotype, and medication recommendations. The visual map was designed to provide a clear and predictable structure of this information for all drugs, including drugs like warfarin that have multiple relevant biomarkers (Figure 4) . The tabs were reordered, placing boxed warnings and recommendations first. The remaining information was provided in the second tab, organized by product label section. This layout was intended to draw attention to the most relevant information first, while also providing access to the label information in the second tab. The box including links to other resources, including to the original product label used for the annotation, was modified to be visible at all times.
Usability evaluation
Sixteen pharmacists representing a variety of clinical practice environments, with experience ranging from 2 months to >20 years, participated in the usability evaluation. Most of them were clinical pharmacists (9) . Of those, a majority (5) were nursing home consultant pharmacists (Table 3 ). All pharmacists who agreed to participate completed the evaluation.
Task completion time
To verify that the order of presentation was not a factor in task completion, we confirmed that task completion time and order were not correlated (r 2 ¼ 0.02, P ¼ .08). Task completion times followed a lognormal distribution, requiring the use of KruskalWallis instead of ANOVA. Kruskal-Wallis results indicated significant differences between the resources ( Figure 5 ) (Kruskal-Wallis, P ¼ .001). Search tasks were completed more quickly with the version 2.0 resource (mean 107.5 s) as compared to both the FDA table (mean 240.2 s; Dunn, P ¼ .003) and PharmGKB (mean 188.9 s; Dunn, P ¼ .0087). Search tasks using the original PGx 1.0 prototype (mean 143.3 s) were completed significantly faster than the FDA table (Dunn, P ¼ .047). All other pairs were not statistically significantly different.
Task correctness
A Chi-square test with a Bonferroni correction showed a difference among the resources in rate of task correctness (N ¼ 128,
significantly better than all other resources (P ¼ .006) and was the only resource in which 100% of answers were found correctly (Table 4) . Of the incorrect answers (22), 2 involved timeouts (maximum 10 min), 6 involved participants giving up, and in the remaining 14, they found answers they incorrectly believed were correct.
System usability scale scores
The SUS score data were normally distributed, allowing for use of ANOVA. Significant differences in SUS scores exist between the various resources ( Figure 6 ) (ANOVA, P < .0005). As variances were not equal, Games-Howell was used for post hoc analysis. 37 2. A physician has a patient with rheumatoid arthritis. She has had genotyping performed for all major pharmacogenes, and results indicate she is heterozygous *3A (1 copy of *3A, 1 copy of *1) for TPMT. The doctor wants to know if she can prescribe azathioprine for this patient.
Consider lower dose 3. Why should a patient with a CYP2C19 genotype other than *1 limit his exposure to citalopram to 20 mg/day?
Poor metabolizers are at risk for QT prolongation 4. A postpartum breastfeeding mother tried to pick up her medications after being released from the hospital. The community pharmacist refused to fill the prescription for codeine because of a possible genetic issue. Why is the community pharmacist refusing to fill a codeine prescription for this patient?
Codeine should not be given to breastfeeding mothers due to the risk of neonate morphine overdose if the mother is an unknown ultra-rapid metabolizer Pharmacists' reactions to pharmacogenomics information resources Participants in both the qualitative inquiries and the evaluations indicated that while the information provided by our pharmacogenomics resource was important, a stand-alone web interface would not be adequate for effective use of pharmacogenomics information in the clinic. Ideally, they would prefer a resource that is integrated into the electronic health record (EHR) and connects actual patient genotype data with FDA-approved drug label information. They also felt that the information provided by the FDA did not always give them satisfactory recommendations on how to proceed with specific patients. Recommending that a dose be lowered is not as helpful as recommending a specific dose; recommending that an alternative drug be given is not as helpful as recommending a list of alternatives. Furthermore, for many drugs, other nongenomic factors have a significant impact on the optimal dose for a given patient, such as age, weight, renal function, and other clinical factors. As a result, pharmacists felt that the information and recommendations provided by the FDA product labels were insufficient without patient-specific clinical data and recommendations based on that data in addition to genotype data.
DISCUSSION
Clinicians of all types struggle with pharmacogenomics information. 7, 9, 21, 38, 39 To make a decision regarding the applicability of drugs for patients, clinicians must incorporate information about genes, how they interact with drugs, the predicted phenotypes of given gene variants, and the phenotypes associated with those variants with respect to affected drugs. 39 Interpreting this information presents multiple challenges, including unfamiliar and potentially confusing notation for describing gene variants and phenotypes. Studies have shown that clinicians feel poorly informed about pharmacogenomics testing, and that they have a difficult time interpreting test results 7, 9 and the complex interactions between drugs and genes. 39 Efforts at meeting clinicians' pharmacogenomics information needs are under way, such as the work of Devine et al. 40 to develop pharmacogenomics alerts within a computerized provider order entry system. Devine, et al. found in their recent usability study with clinicians found that clinicians seek trustworthy, relevant, dosing-related recommendations. 40 Another recent study found that clinicians welcome pharmacogenomics information for the clopidogrel-CYP2C19 drug-gene interaction, and that they would like supplementary information about the interaction due to insufficient knowledge about pharmacogenomics. 41 Pharmacists, as trained drug information experts, are naturally poised to support the incorporation of pharmacogenomics into clinical practice, but they also struggle with pharmacogenomics information. 22, 29, 39, 42 Many groups, including the Pharmacogenomics Research Network, CPIC, and eMERGE, as discussed previously, are implementing clinical pharmacogenomics testing, producing evidence-based guidelines, and incorporating genetic testing results into clinical decisionmaking. All of these efforts have hurdles to overcome related to how to structure and present genetic data and evidence in a way that is clinically actionable.
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One solution to managing this overwhelming amount of information is to present structured, concise, relevant information, particularly with visual depictions of the relationships between gene variants, drugs, and phenotypes. Our evaluation suggests that these techniques can help pharmacists to access, understand, and incorporate pharmacogenomics information into their decision-making process, as compared to other pharmacogenomic information resources. Version 2.0 supported pharmacists in answering pharmacogenomicsrelated drug questions more successfully than the FDA table on all 3 measures (task completion time, correctness, and perceived usability) and more successfully than PharmGKB on 2 out of 3. Participants saved 81.4 s, on average, when completing tasks using version 2.0 compared to PharmGKB, a 75.7% decrease, and 132.7 s compared to the FDA table, a 123.4% decrease. Version 2.0 was the only resource on which users answered every question correctly.
Some of the differences in performance may be due to a difference in focus among the resources. For instance, the FDA information provided by these resources is not the only clinically important pharmacogenomics information available: PharmGKB is built around the clinical guidelines developed by the CPIC. 17 Incorporating CPIC guidelines into our resource and integrating them alongside the drug label information is a potential future improvement. Also, the FDA table is not intended to be a clinical information resource providing practice recommendations or supporting clinical decision-making. In contrast, our resource is a novel implementation of pharmacogenomics information, structured by a clinically informed, detailed semantic model that allows us to present the information in a highly usable, searchable way, while also providing the opportunity to connect the information to other sources of information, including guidelines, evidence, and patient-specific data.
The goal of this project was to develop an effective method of imparting pharmacogenomics information to clinicians, specifically pharmacists, by providing clinically actionable pharmacogenomics drug information connected to relevant FDA-mandated product label sources. We aimed to access and present that information faster, more completely, with a more satisfactory user experience than available alternatives. However, a key piece of information missing from our resource, as well as all other currently available resources, is accurate patient data, both clinical and genotype. The semantic model on which this resource is built is capable of connecting patient data from EHRs to evidence from sources such as product labels, guidelines, and institutional policies. We have achieved the first necessary steps in building the resource, designing a highly usable way of presenting pharmacogenomics information, and evaluating it against alternative resources, with positive results in performance and usability. Our next step is to connect it to patient data so pharmacists have access to patient-specific, clinically relevant, actionable information at the point of care. Furthermore, pharmacists indicated throughout this project that a stand-alone system would not fully support their needs; they want the information integrated into their existing systems, including computerized provider order entry systems and EHRs. Understanding how best to achieve this requires careful study of current workflows of pharmacists and other clinicians as they engage with medication-related pharmacogenomics information.
LIMITATIONS
Limitations include a small sample size and number of tasks, which limit the generalizability of the conclusions. We cannot claim that any one of the interface changes definitely improved usability or performance. Clinical implementation of genetic testing and genotypeguided clinical decision support is necessary to determine improved clinical outcomes. Some pharmacogenomics information from product labels might be of limited value due to the lack of actionable recommendations and connection to patient-specific genetic data. Similarly, other consensus PGx guidelines (CPIC) exist and are commonly used to drive decision support. However, we chose to focus on FDA product label information as a starting point as it is the US regulatory standard for drug information. The information was provided by all assessed resources, and the tasks and correct answers were written based solely on that information. Participants used only the FDA labeling portion of the PharmGKB.org website rather than the complete site to ensure that they were using the same type of information to complete tasks across each resource. We also did not compare tertiary resources that provide pharmacogenomics information because we were focusing on sources that provide product label statements directly. Finally, further development and implementation of the system as an integrated resource will require long-term effort and institutional support. Much of the expense lies in the translation of FDA pharmacogenomics information from free text into a structured semantic model. 28 Community adoption of a common model for representing key pharmacogenomics details would reduce this expense. Future work will include exploring how this resource can fit within pharmacists' workflow; expanding the information and sour- Figure 6 . Box plot of System Usability Scales by resource: boxes and whiskers represent median and interquartile ranges, asterisks represent outliers, solid circles represent mean SUS scores ces of information to include CPIC guidelines, local practice guidelines, and tertiary information sources; and, most importantly, connecting it to patient genetic and clinical data to provide patientspecific recommendations.
CONCLUSIONS
Our pharmacist-focused resource supports pharmacogenomics information tasks more successfully than alternative resources. In the process of designing this resource, we identified a model for displaying pharmacogenomics information that pharmacists find understandable and useful while seeking this information to make drug decisions. The model for presenting pharmacogenomics information and the semantic model on which the resource is built are necessary for effective implementation of patient-specific pharmacogenomics decision support connected to EHRs. Researchers and designers of alerts and practice guidelines related to pharmacogenomics may find this model to be a strong guideline for presenting pharmacogenomics information to clinicians in a concise and accessible way.
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